USX:PRXL - PAREXEL International Corp (USD 88.08) PAREXEL International Corp
Sector: Health Technology, Industry: Medical Specialties
Add to Watchlist

Yahoo Finance
Note: This stock seems to be inactive

USD 88.08    -0.020 (-0.02%)
Show Basic Chart | 3M    6M    1Y    3Y    5Y          

29 Sep 2017


29 Sep 2017

Day Change: -0.020 (-0.02%)

52 Wk Range: 51.16 - 88.1

Day's Range: 88.07 - 88.1

Last Volume: 7,021,106

Current Yield: 0%

Projected Yield: 0%

Open: USD 88.1

2 Aug 2018

Metric PRXL S.Median
Beta NA 0.78
VaR NA 21.09
E.Shortfall NA 29.34
Liquidity NA 92.34K


29 Sep 2017

PE: 42.85

Market Cap: 4.6B

Price Over Book: 7.246

Price Over Sales: 1.88

Return On Assets: 4.6%

Return On Equity: 16.9%

Price Over NAV: [Friends Only]


CEO: Josef H. von Rickenbach

Headquarters: Waltham

Employees: 18,600

Sector: Health Technology

Industry: Medical Specialties

Useful Links


PAREXEL International Corporation, a biopharmaceutical services company, provides clinical research, clinical logistics, medical communications, consulting, commercialization, and advanced technology products and services for pharmaceutical, biotechnology, and medical device industries worldwide. The company operates in three segments: Clinical Research Services (CRS), PAREXEL Consulting Services (PC), and PAREXEL Informatics (PI). The CRS segment offers clinical trials management, observational studies, patient/disease registries and post-marketing surveillance, data management and biostatistics, epidemiology and health economics/outcomes research, clinical logistics, pharmacovigilance, commercialization, and clinical pharmacology, as well as related medical affairs, patient recruitment, and investigator site services. The PC segment provides technical expertise and advice in various areas, such as drug development, regulatory affairs, product pricing and reimbursement, commercialization, and strategic compliance; and market development, product development, and targeted communications services in the support of product launch, as well as offers solutions to address client issues associated with product development, registration, and commercialization. The PI segment provides information technology solutions comprising ClinPhone randomization and trial supply management solutions, medical imaging services, IMPACT clinical trial management systems, LIQUENT InSight regulatory information management software and professional services, DataLabs electronic data capture systems, Web-based portals, systems integration services, electronic patient reported outcomes, and patient diary applications, as well as centralized assessment services for patient technology solutions, such as spirometry, electronic clinical outcomes, and wearables. The company was founded in 1983 and is headquartered in Waltham, Massachusetts.